STAT-related profiles are associated with patient response to targeted treatments in locally advanced SCCHN

Translational Oncology

Volumn 4, Issue 1, 2011, Pages 47-58

  Kotoula, Vassiliki ^a   Lambaki, Sofia ^a   Televantou, Despina ^a   Kalogera Fountzila, Anna ^a   Nikolaou, Angelos ^a   Markou, Konstantinos ^a   Misailidou, Despina ^b   Syrigos, Konstantinos N ^c   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DASATINIB; PROTEIN CAV1; PROTEIN IGFBP2; PROTEIN MSN; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MALE; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 79251572997     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10217     Document Type: Article

References (80)

1. Licitra L and Felip E (2009). Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(suppl 4), 121-122.
2. Pivot X and Felip E (2008). Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(suppl 2), ii79-ii80.
3. FDA (2006). FDA approves first head & neck cancer treatment in 45 years data shows treatment with Erbitux extends survival. FDA News Release P06-34.
4. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354, 567-578.
5. Vermorken JB, Herbst RS, Leon X, Amellal N, and Baselga J (2008). Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112, 2710-2719.
6. Egloff AM and Grandis JR (2008). Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol 35, 286-297.
7. Cohen EE (2006). Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24, 2659-2665.
8. Egloff AM and Grandis JR (2009). Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive bio-markers and combination treatment with Src inhibitors. J Oncol 2009, 896407.
9. Bonomi PD, Buckingham L, and Coon J (2007). Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13, s4606-s4612.
10. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626-1634.
11. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26, 374-379.
12. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, and Tannapfel A (2003). Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22, 4757-4759.
13. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A, Raimondi AR, Jufe R, Itoiz M, Gao Y, et al. (2007). Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13, 4964-4973.
14. Silva CM (2004). Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23, 8017-8023.
15. Quesnelle KM, Boehm AL, and Grandis JR (2007). STAT-mediated EGFR signaling in cancer. J Cell Biochem 102, 311-319.
16. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, and Gutkind JS (2006). Molecular cross-talk between the NF-κB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8, 733-746.
17. Watson CJ and Neoh K (2008). The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol 19, 401-406.
18. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, Leonard WJ, and Broxmeyer HE (2000). Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 192, 719-728.
19. Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, and Grandis JR (2008). Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res 14, 7682-7690.
20. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, and Harari PM (2009). Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15, 1585-1592.
21. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, and Harari PM (2009). Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8, 696-703.
22. Johnson FM, Saigal B, Talpaz M, and Donato NJ (2005). Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11, 6924-6932.
23. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. (2004). Discovery of N -(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47, 6658-6661.
24. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354, 2531-2541.
25. Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, et al. (2008). Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14, 352-359.
26. Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, and Evans TR (2009). Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15, 6232-6240.
27. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng S, et al. (2009). Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15, 7421-7428.
28. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, and Clark E (2007). Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67, 2226-2238.
29. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, and Huang F (2007). Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8, R255.
30. Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, et al. (2009). MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol 2009, page typefirst305908/page.
31. Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, et al. (2008). Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 99, 1775-1785.
32. Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, Roarty K, and Benveniste EN (2008). Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 14, 4694-4704.
33. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 25, 402-408.
34. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, and Nutt CL (2006). Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65, 1181-1188.
35. Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, and Iwase H (2006). Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 13, 885-893.
36. Lassmann S, Schuster I, Walch A, Gobel H, Jutting U, Makowiec F, Hopt U, and Werner M (2007). STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pa th o l 60, 173-179.
37. Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, and Lobie PE (2008). Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1- stimulated oncogenic transformation of the immortalized human mammary epithelial cell. Endocrinology 149, 2219-2229.
38. Lai SY and Johnson FM (2010). Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 13, 67-78.
39. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, and Tweardy DJ (1998). Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Investig 102, 1385-1392.
40. Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, et al. (2006). Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst 98, 181-189.
41. Arany I, Chen SH, Megyesi JK, Adler-Storthz K, Chen Z, Rajaraman S, Ember IA, Tyring SK, and Brysk MM (2003). Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett 199, 83-89.
42. Shaw RJ, Hall GL, Lowe D, Liloglou T, Field JK, Sloan P, and Risk JM (2008). The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. Arch Otolaryngol Head Neck Surg 134, 251-256.
43. Engelman JA, Zhang XL, Galbiati F, and Lisanti MP (1998). Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett 429, 330-336.
44. Zhang H, Su L, Muller S, Tighiouart M, Xu Z, Zhang X, Shin HJ, Hunt J, Sun SY, Shin DM, et al. (2008). Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. Br J Cancer 99, 1684-1694.
45. Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, Masterson J, Patel S, Cordon-Cardo C, Prystowsky MB, et al. (2005). Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg 131, 10-18.
46. Madan R, Brandwein-Gensler M, Schlecht NF, Elias K, Gorbovitsky E, Belbin TJ, Mahmood R, Breining D, Qian H, Childs G, et al. (2006). Differential tissue and subcellular expression of ERM proteins in normal and malignant tissues: cytoplas-mic ezrin expression has prognostic significance for head and neck squamous cell carcinoma. Head Neck 28, 1018-1027.
47. Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, and Taniguchi S (2004). Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res 10, 572-580.
48. Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, and Zhang W (2007). Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104, 11736-11741.
49. Fukushima T, Tezuka T, Shimomura T, Nakano S, and Kataoka H (2007). Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 282, 18634-18644.
50. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, and Zhang W (2005). Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 4, 7.
51. Martin JL and Baxter RC (2007). Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylino-sitol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 148, 2532-2541.
52. Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, and Eto H (2005). Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep 13, 341-345.
53. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE, Ariga H, and Cohen P (2009). PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 23, 169-175.
54. Moore MG, Wetterau LA, Francis MJ, Peehl DM, and Cohen P (2003). Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 105, 14-19.
55. Marucci G, Morandi L, Magrini E, Farnedi A, Franceschi E, Miglio R, Calo D, Pession A, Foschini MP, and Eusebi V (2008). Gene expression profiling in glio-blastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 453, 599-609.
56. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, and Pollak M (2008). Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14, 6944-6954.
57. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, and Kumar R (2007). Insulinlike growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13, 4291-4299.
58. Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, and Su WC (2003). Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 89, 344-349.
59. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, and Frank DA (2009). Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 7, 966-976.
60. Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, et al. (2010). Nuclear localization of signal transducer and activator of transcription 3 in head and neck squa-mous cell carcinoma is associated with a better prognosis. Clin Cancer Res 16, 2427-2434.
61. Xi S, Zhang Q, Gooding WE, Smithgall TE, and Grandis JR (2003). Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 63, 6763-6771.
62. Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall TE, and Grandis JR (2002). Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 21, 2846-2853.
63. Wykosky J and Debinski W (2008). The EphA2 receptor and ephrinA1 li-gand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6, 1795-1806.
64. Miyazaki T, Kato H, Fukuchi M, Nakajima M, and Kuwano H (2003). EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103, 657-663.
65. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, Engenhart-Cabillic R, and An HX (2008). Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 19, 151-156.
66. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, and Johnson FM (2009). Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15, 4423-4430.
67. Rivera RS, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Pehlivan D, Yamanaka N, Shimizu K, et al. (2008). Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies. Oncol Rep 19, 1079-1084.
68. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, and Poulsen HS (2007). Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 5, 283-293.
69. Burtness B (2005). The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 5, 1085-1093.
70. Leroy C, Fialin C, Sirvent A, Simon V, Urbach S, Poncet J, Robert B, Jouin P, and Roche S (2009). Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. Cancer Res 69, 2279-2286.
71. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, and Pusztai L (2010). Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther 9, 1120-1127.
72. Lim LH and Pervaiz S (2007). Annexin 1: the new face of an old molecule. FASEB J 21, 968-975.
73. Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV, Suarez Nieto C, and Rodrigo JP (2004). Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 164, 73-79.
74. Alves VA, Nonogaki S, Cury PM, Wunsch-Filho V, de Carvalho MB, Michaluart-Junior P, Moyses RA, Curioni OA, Figueiredo DL, Scapulatempo-Neto C, et al. (2008). Annexin A1 subcellular expression in laryngeal squamous cell carcinoma. Histopathology 53, 715-727.
75. Nomura H, Uzawa K, Yamano Y, Fushimi K, Nakashima D, Kouzu Y, Kasamatsu A, Ogawara K, Shiiba M, Bukawa H, et al. (2009). Down-regulation of plasma membranous Annexin A1 protein expression in premalignant and malignant lesions of the oral cavity: correlation with epithelial differentiation. J Cancer Res Clin Oncol 135, 943-949.
76. Schetter AJ, Nguyen GH, Bowman ED, Mathe EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, and Harris CC (2009). Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adeno-carcinoma. Clin Cancer Res 15, 5878-5887.
77. Xu QY, Gao Y, Liu Y, Yang WZ, and Xu XY (2008). Identification of differential gene expression profiles of radioresistant lung cancer cell line established by fractionated ionizing radiation in vitro. Chin Med J (Engl) 121, 1830-1837.
78. Nair S, Hande MP, and Lim LH (2010). Annexin-1 protects MCF7 breast cancer cells against heat-induced growth arrest and DNA damage. Cancer Lett 294, 111-117.
79. Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM (2005). Phosphoryla-tion and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
80. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, et al. (2009). Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15, 2361-2372.